Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C

Scand J Infect Dis. 1999;31(2):115-8. doi: 10.1080/003655499750006119.

Abstract

A total of 172 Swedish patients treated with interferon-alpha for at least 24 weeks and followed-up > or =24 weeks after treatment was stopped were analysed for pre-treatment factors of importance for achieving a virological sustained response (SR). Furthermore, the predictive value for a virological SR of a positive or negative HCV RNA test at week 12 of treatment was evaluated. A low baseline viral load and genotype non-1b were pre-treatment factors indicating a favourable response. Thus, 44% (38/86) of patients with a low baseline viral load vs. only 16% (14/86) of those with a high viral load had a virological SR (p<0.0001). Of patients with a negative qualitative HCV RNA test after 12 weeks of interferon treatment, 46% (44/95) had virological SR, whereas only 5.9% (4/68) of those with a positive test had (p<0.0001). Prolonged ( > 6 months) treatment with interferon-alpha tended to increase the chance of virological SR (p<0.052).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Alanine Transaminase / metabolism
  • Female
  • Genotype
  • Hepacivirus / genetics
  • Hepacivirus / physiology*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon Type I / therapeutic use
  • Interferon-alpha / therapeutic use*
  • Liver / enzymology
  • Male
  • Middle Aged
  • RNA, Viral / blood
  • Recombinant Proteins
  • Sex Factors
  • Treatment Outcome
  • Viral Load*

Substances

  • Interferon Type I
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Alanine Transaminase